ACE and chronic kidney disease: In previous studies, VLPD produced a significant decrease of proteinuria, reducing phosphate burden and renal disease progression in CKD patients, also in patients treated with angiotensin converting enzyme-inhibitors, who did not achieve a satisfying proteinuria reduction with the drug [15].